At least 3 months of anticoagulation is the minimum (initial treatment phase) for all patients with DVT or PE, after which the decision is whether to stop or continue indefinitely (extended phase) based on the balance between recurrence risk and bleeding risk.
The core determinant is how the event was provoked.
Provoked by a major transient/reversible risk factor (surgery >30 min under general anesthesia, hospitalization/bedrest ≥3 days, major trauma/fracture).
Stop anticoagulation after 3 months — recurrence risk is low (<1–3%/year) and extending to 24 months provides no benefit.
Some experts extend to 6 months if the PE was large, with RV dysfunction, or residual symptoms.
Unprovoked (no identifiable risk factor) or weakly provoked (minor transient factor — estrogen, pregnancy, minor surgery/leg injury)
Recurrence risk is high (~10% at 1 year, ~30–40% at 10 years), so indefinite (extended) anticoagulation is generally recommended if bleeding risk is not high.
– Stop at 3 months if high bleeding risk (≥2 of: age >65, antiplatelet use, CrCl <50, anemia, prior bleeding).
Risk stratification tools (e.g., HERDOO2 in women) can identify low-risk patients who may safely discontinue.
Guidelines differ on minor transient factors: NICE/ASH treat them like provoked events (stop after primary treatment), while ESC/ERS suggest considering extended therapy.
Persistent/chronic risk factors (active cancer, antiphospholipid syndrome, IBD, autoimmune disease).
Indefinite anticoagulation is recommended. For active cancer, continue until the malignancy is resolved.
Antiphospholipid syndrome requires a VKA (warfarin), not a DOAC.
A second unprovoked VTE also warrants indefinite therapy.
Extended-phase dosing: DOACs are preferred over VKA.
After at least 3–6 months of full-dose therapy, reduced-intensity dosing can be used for secondary prevention — apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily.
Extended therapy is not a fixed duration; it continues without an anticipated stop date and requires periodic reassessment of the risk–benefit balance.
Major transient risk factor (surgery, trauma, hospitalization, immobility):
Stop at 3 months. Minor transient risk factor (estrogen use, long travel, minor leg injury, pregnancy/postpartum):
Usually 3 months, then stop; some clinicians extend based on bleeding risk and recurrence risk.
Unprovoked or no identifiable risk factor:
Offer extended therapy (no scheduled stop date) if bleeding risk is low to moderate, with periodic reassessment (at least annually).
Recurrence risk is roughly 10% at 1 year and about 30% at 5 years off treatment.
Persistent risk factor (active cancer, antiphospholipid syndrome)
Extended therapy. Cancer: continue while cancer is active or under treatment (DOAC or LMWH).
Antiphospholipid syndrome (especially triple-positive): warfarin is preferred over DOACs, indefinitely.
Recurrent VTE:Generally indefinite.
Extended-phase dosing: After 6 months of full dose, apixaban 2.5 mg BID or rivaroxaban 10 mg daily are options with lower bleeding than full dose and similar efficacy for recurrence.
Superficial vein thrombosis:
Clot ≥5 cm or within 3 cm of the saphenofemoral junction: prophylactic-dose fondaparinux 2.5 mg daily (or rivaroxaban 10 mg) for 45 days.
Smaller or lower-risk clots: symptomatic care, or a shorter course.
Isolated distal DVT (calf): 3 months if treated; some are managed with serial imaging instead.
Subsegmental PE with no proximal DVT: may be observed in low-risk patients.
D-dimer after stopping and risk scores can help estimate recurrence but aren’t universally adopted.
For a PE clearly provoked by a major transient risk factor e.g., surgery/trauma within ~3 months, hospitalization with immobilization, estrogen therapy, pregnancy/puerperium), anticoagulation is generally continued for 3 months, then stopped if there is no other ongoing indication.
Duration by provocation
|PE provoked by a major transientfactor 3 months
PE associated with a **minor/persistent** provoking factor-At least 3 months, then reassess recurrence vs bleeding risk; some clinicians use 3–6 months
PE with persistent risk factor (e.g., active cancer, ongoing immobility)
Continue while risk persists; often **indefinite if risk and bleeding profile favor it.
Pregnancy-associated PE anticoagulate through pregnancy and at least 6 weeks postpartum, with total treatment of at least 3 months.
Provoked is a major reversible trigger carries a low 5-year recurrence risk (~3%), whereas weaker, ambiguous, or persistent risk factors warrant individualized reassessment rather than automatic discontinuation at 3 months.
At the 3-month mark, reassessment:
Whether the provoking factor was truly transient and major Recurrence risk: residual DVT, unprovoked component, prior VTE, thrombophilia, male sex, elevated D-dimer Bleeding risk and patient preference For selected intermediate-risk patients, on-treatment D-dimer can help refine the decision; a positive D-dimer may favor continued therapy.
Practical approach
Major transient provocation + low bleeding risk:stop at 3 months.
Minor/persistent provocation: treat at least 3 months, commonly 3–6 months, then reassess.
Recurrent VTE or persistent major risk factor: consider extended indefinite anticoagulation, with periodic reassessment.
ASH guidance is slightly more conservative, suggesting 3–6 months** for VTE provoked by a transient risk factor, while ACCP-style guidance supports stopping at 3 months for clearly transient provocation.